PL4463452T3 - Modulatory translacji c-myc mrna i ich zastosowania w leczeniu nowotworu - Google Patents
Modulatory translacji c-myc mrna i ich zastosowania w leczeniu nowotworuInfo
- Publication number
- PL4463452T3 PL4463452T3 PL23728146.4T PL23728146T PL4463452T3 PL 4463452 T3 PL4463452 T3 PL 4463452T3 PL 23728146 T PL23728146 T PL 23728146T PL 4463452 T3 PL4463452 T3 PL 4463452T3
- Authority
- PL
- Poland
- Prior art keywords
- applications
- cancer treatment
- mrna translation
- myc mrna
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL291418A IL291418B2 (en) | 2022-03-16 | 2022-03-16 | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment |
| PCT/US2023/015237 WO2023177700A2 (en) | 2022-03-16 | 2023-03-15 | C-myc mrna translation modulators and uses thereof in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4463452T3 true PL4463452T3 (pl) | 2025-11-12 |
Family
ID=86657273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23728146.4T PL4463452T3 (pl) | 2022-03-16 | 2023-03-15 | Modulatory translacji c-myc mrna i ich zastosowania w leczeniu nowotworu |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12344600B2 (pl) |
| EP (1) | EP4463452B1 (pl) |
| DK (1) | DK4463452T3 (pl) |
| ES (1) | ES3045034T3 (pl) |
| IL (1) | IL291418B2 (pl) |
| PL (1) | PL4463452T3 (pl) |
| WO (1) | WO2023177700A2 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096660A1 (en) * | 2023-10-30 | 2025-05-08 | Pretzel Therapeutics, Inc. | Compositions and inhibitors of polrmt |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1709019E (pt) | 2004-01-12 | 2007-08-27 | Serono Lab | Derivados de tiazol e sua utilização |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| EP2007393B1 (en) | 2006-04-07 | 2013-08-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| CN101657471B (zh) | 2006-12-06 | 2013-07-03 | 史密丝克莱恩比彻姆公司 | 二环化合物及其作为抗糖尿病药的用途 |
| MX2009011358A (es) | 2007-04-20 | 2009-11-05 | Schering Corp | Derivados de pirimidinona y metodos para su uso. |
| AU2008268574C1 (en) | 2007-06-22 | 2014-03-20 | Anima Cell Metrology | Fluorescent labeling of transfer RNA and study of protein synthesis |
| WO2009051909A1 (en) | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr cellular processing and uses thereof |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB0813740D0 (en) | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| AU2011292285A1 (en) | 2010-08-16 | 2013-01-31 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| WO2012077655A1 (ja) | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体 |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| US10526345B2 (en) | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| US20170340636A1 (en) | 2016-05-26 | 2017-11-30 | Board Of Regents, The University Of Texas System | Compositions and methods for inhibition of autophagy |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| JP7217712B2 (ja) | 2017-01-24 | 2023-02-03 | シーエスピーシー ジョォンチィ ファーマシューティカル テクノロジー （シージアジョァン）カンパニー，リミテッド | Ｌｓｄ１阻害剤、その製造方法及び応用 |
| WO2019018795A1 (en) * | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| CA3083000A1 (en) * | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| US20190374526A1 (en) * | 2018-06-06 | 2019-12-12 | Merck Sharp & Dohme Corp. | Substituted Heterocyclic Compounds as Inhibitors of PRDM9 |
| PE20220572A1 (es) | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
-
2022
- 2022-03-16 IL IL291418A patent/IL291418B2/en unknown
-
2023
- 2023-03-15 EP EP23728146.4A patent/EP4463452B1/en active Active
- 2023-03-15 DK DK23728146.4T patent/DK4463452T3/da active
- 2023-03-15 WO PCT/US2023/015237 patent/WO2023177700A2/en not_active Ceased
- 2023-03-15 US US18/838,246 patent/US12344600B2/en active Active
- 2023-03-15 PL PL23728146.4T patent/PL4463452T3/pl unknown
- 2023-03-15 ES ES23728146T patent/ES3045034T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES3045034T3 (en) | 2025-11-27 |
| IL291418B2 (en) | 2024-05-01 |
| IL291418A (en) | 2023-10-01 |
| WO2023177700A3 (en) | 2023-10-26 |
| IL291418B1 (en) | 2024-01-01 |
| WO2023177700A2 (en) | 2023-09-21 |
| US12344600B2 (en) | 2025-07-01 |
| DK4463452T3 (da) | 2025-10-13 |
| US20250109128A1 (en) | 2025-04-03 |
| EP4463452A2 (en) | 2024-11-20 |
| EP4463452B1 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006134A (es) | Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos. | |
| SI4497438T1 (sl) | Triciklični inhibitorji parp1 in njihove uporabe | |
| EP4468534A4 (en) | CONNECTOR SHEET AND CONNECTOR | |
| IL311339A (en) | Gelma polymer compositions and uses thereof | |
| PT3773738T (pt) | Conjugados anticorpos-fármaco e suas utilizações para o tratamento do cancro | |
| EP4161586A4 (en) | Granzyme b directed imaging and therapy | |
| EP4251650A4 (en) | Novel conjugate molecules targeting cd39 and tgfbeta | |
| EP4404957A4 (en) | CANCER THERAPY COMPOSITIONS AND THEIR USES | |
| SI4058474T1 (sl) | Sestavki in metode za zdravljenje egfr pozitivnih rakov | |
| EP4486728A4 (en) | IONIZABLE LIPIDS AND COMPOSITIONS CONTAINING THEM | |
| IL299334A (en) | Antibody-antidrug-tissue factor conjugates and their use in cancer treatment | |
| DK4463452T3 (da) | c-Myc mRNA-TRANSLATIONSMODULATORER OG ANVENDELSER DERAF I CANCERBEHANDLING | |
| IL287043A (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| EP4602542A4 (en) | Divisible non-fungible token and its applications | |
| DK4125842T3 (da) | Samtidig indgivelse af mirdametinib og lifirafenib til anvendelse til behandling af kræftformer | |
| EP4430081A4 (en) | CANCER COMBINATION THERAPY WITH MEMORY NK CELLS AND BISPECIFIC ANTICANCER MOLECULES | |
| EP4334718A4 (en) | ASSESSMENT AND TREATMENT OF CANCER | |
| IL309249A (en) | Conjugates including phosphoantigens and their use in therapy | |
| IL316805A (en) | Substances that function as modulators of cMYC-mRNA translation and their uses in cancer treatment | |
| HK40120154A (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| HK40094259A (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| EP3960242A4 (en) | CONJUGATE AND CANCER THERAPEUTIC | |
| IL312844A (en) | Methods and compositions for treating cancer | |
| IL314241A (en) | Topical compositions and uses therof | |
| PL3873510T3 (pl) | Tiostrepton i witamina e-tpgs w leczeniu nowotworu |